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Background: Myeloid and plasmacytoid dendritic cell (DC) subsets have been recently identi-
fied in the human lung based on their differential expression of Blood DC Antigens 1e3
(BDCAs). We investigated the expression of these antigens by isolated human pulmonary CD1aþ
DCs, namely Langerhan’s cells.
Methods: Using an in vitro cell culture system we successfully isolated a population of rela-
tively pure (>70%) CD1aþ cells from human lung tissue (nZ 5 subject samples) and stained
these with antibodies against the myeloid DC markers BDCA1 (CD1c) and BDCA3 (CD303), the
plasmacytoid DC marker BDCA2 (CD141), the Langerhan’s cell marker Langerin and the matu-
ration marker CD83.
Results: Among different subject samples, the isolated CD1aþ cells showed variable expression
of Langerin, BDCAs and CD83. Interestingly, in two subject samples, which contained >70%
CD83þ mature CD1aþ cells, >50% of the cells were positive for all of the BDCAs.
Conclusions: We conclude that isolated pulmonary CD1aþ DCs in vitro have the capacity to
express both myeloid and plasmacytoid BDCA markers and that rather than subset restriction
in pulmonary DCs, a significant degree of flexibility/plasticity can be induced, albeit experi-
mentally.
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CD1aþ cells, namely Langerhan cells (LCs), were the first
dendritic cells (DCs) to be identified in the lung. Relatively
recently, flow cytometry was used to identify three human
lung DC subsets expressing the blood DC antigen 1 (BDCA1).
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(m) DCs type 1, plasmacytoid (p) DCs and mDCs type 2,
respectively.1,2 However, the microanatomical location of
these DC subsets within lung tissue is uncertain.3,4 Further-
more, it is not clear whether pulmonary LCs comprise
a fourth distinct DC subset or not. Flow cytometry of cells
from lung tissue digests and bronchoalveolar lavage fluid
suggest that a subpopulation of CD1aþ DCs expresses the
BDCA1 CD1c, and could therefore be classified as pulmonary
mDCs type 1.1,5 Studies aimed at classifying pulmonary DCs
are challenging because these cells are relatively infrequent.
Using a method previously described by us that produces
a CD1aþ-enriched population from human lung tissue
digests,6 we aimed to characterize human lung CD1aþ cells
based on their expression of BDCAs 1e3.1
Materials and methods
Isolation of lung DCs
DCs were isolated from lung of grossly normal appearance
after resection for lung carcinoma, approved by the Royal
Brompton and Harefield Ethical Committee (nZ 8 subjects).
DCs were isolated at an intermediate stage of alveolar
epithelial cell isolation.6 Lung tissue was perfused exten-
sively (>10 times, 20 ml/5 cm3 tissue) with normal saline to
remove alveolar macrophages. The 8th to 10th perfusate
was examined for the presence of alveolar macrophages and
other leukocytes. If they were >1 104/ml, further perfu-
sion was performed to ensure that there were no alveolar
macrophages left. The tissue was then inflated with trypsin
(T8003, Sigma), incubated, 45 min at 37 C, then minced
with scissors in the presence of newborn calf serum (NCS,
Invitrogen, Paisley, UK). Use of trypsin, for no longer than
45 min, ensured that the epithelium was stripped from the
underlying interstitial tissue, without significant collagen
and elastin degradation, thus liberating only the epithelial
cells and any associated epithelial DCs. The mince was
incubated with 0.25% DNase (Sigma), filtered (40 mm mesh),
the filtrate containing liberated cells was centrifuged (300 g)
and the cell pellet re-suspended in DCCM-1 media (React
Scientific, Troon, UK). These cells were plated onto culture
plastic. The non-adherent, epithelial cell-enriched cells
were removed. Adherent cells were immunostained for DC
specific markers and for CD68 (the last to detect
contaminating macrophages).
Immunocytochemistry
The Dako Envision kit (Dako, Ely, UK) was used to detect
human BDCA2 (1:25, overnight; Miltenyi Biotech, Bergisch
Gladbach), BDCA3 (1:25, overnight; Miltenyi Biotech, Guild-
ford, UK), BDCA1(CD1c) (1:200, 3 h; Serotec, Kidlington,
Oxford, UK), CD1a (1:25, overnight; Vector, Burlingame, CA,
USA), CD83 (1:25, overnight; Vector), Langerin (1:50, 3 h;
Beckman Coulter [Immunotech], High Wycombe, UK).
Quantification
At least three fields and more than 300 cells were counted
per marker for each subject.Transmission electron microscopy
Adherent cells were washed in PBS, incubated with 0.25%
trypsin-EDTA (Sigma) for 3 min and 10% NCS added to inacti-
vate the trypsin. The dislodged cells were collected, centri-
fuged and the cell pellet washed with PBS before fixing with
2.5% glutaraldehyde in 0.05 M sodium cacodylate buffer.
Results
In three out of eight subject samples processed there was
an insufficient number of CD1aþ DCs and they were of low
purity (<70% purity). Thus these samples were not immu-
nostained against DC antigens. A CD1aþ DC population of
high purity (CD1aþ cells >70%; CD68þ cells 0%) was isolated
from five subject samples (Table 1). Langerin was highly
expressed (>65% Langerinþ cells) in three of these samples
(# 2, 3, 4). Internalisation of Langerin induces the formation
of Birbeck granules which can be visualised by electron
microscopy; however, none were detected.
Among the subject samples, four showed high expression
of the maturation marker CD83 (>70% CD83þ cells) (# 1, 3,
4, 5). These subject samples also contained high percent-
ages of BDCA3þ cells and in two of these (# 3, 4) there was
also high expression of BDCA1 and BDCA2. Subject sample
# 2, which weakly expressed the maturation marker CD83,
showed low BDCAs 1e3 expression. Fig. 1 illustrates
differences for staining of BDCAs 1e3 between subject
sample # 3 and subject sample # 2.
The antibodies did not crossreact with other antigens,
being negative when applied to alveolar macrophages and
human epithelial cells from the same subjects (except for
weak macrophage positivity for BDCA3, data not shown).
Discussion
Based on the expression of BDCAs, three distinct pulmonary
DC subsets have been identified previously in the lung, but
it is not known whether any of these antigens can be
expressed by pulmonary CD1aþ DCs. We separated CD1aþ
DCs at an intermediate stage of alveolar epithelial cell
isolation.6 Most of the isolated cells contained predomi-
nately (>70%) mature CD1aþ DCs, illustrated by their CD83þ
staining. As pulmonary DCs in vivo have a predominately
immature phenotype,4 we consider that DC maturation was
induced during processing and/or adherence of DC in vitro.
Like CD1a, Langerin is a LC marker. However, there was
a low frequency of Langerin expressing cells in two CD1aþ-
enriched samples, suggesting that CD1a and Langerin are not
necessarily co-expressed. Accordingly, while Langerinþ cells
reside both in the epithelium and subepithelium, CD1aþ cells
reside almost exclusively in the epithelium.7 Lack of ultra-
structural identification of Birbeck granules in these DCs may
reflect thedepletionof thesegranulesduringDCmaturation.8
Four samples contained significant numbers of cells
expressing the mDC type 2 marker BDCA3, whereas two of
these samples also contained a high percentage of cells
expressing the mDC type 1 marker BDCA1 and the pDC
marker BDCA2, suggesting that some DCs in the lung express
all BDCAs 1e3. This was unexpected and in contrast to
previous studies of bronchoalveolar fluid and tissue by us
Table 1 Subject characteristics and percentages of positively stained cells for each marker. Data are provided for each
subject in the chronological order of receipt of sample. Figures in brackets denote the minimum percentage of cells calculated
to be double positive for the marker studied and for CD1a (% double positive cellsZ % marker positive cells - % CD1a negative
cells).
Subject Characteristics
Subject Number Gender Age Smoking Status Pack. Years Type of lung cancer
1 M 83 EX-SM 20 Primary (adeno)
2 M 58 EX-SM 60 Primary (adeno)
3 M 70 C-SM Pipe-smoker Secondary
4 F 53 EX-SM 2 Secondary
5 M 77 EX-SM 50 Primary (adeno)
Immunocytochemistry data
Subject Number CD1a Langerin BDCA1 BDCA2 BDCA3 CD83
1 79 0 (0) 4 (0) 41 (20) 76 (55) 79 (58)
2 77 65 (42) 16 (0) 4 (0) 36 (13) 5 (0)
3 83 79 (62) 57 (40) 68 (51) 88 (71) 76 (59)
4 95 76 (71) 59 (54) 100 (95) 99 (94) 94 (89)
5 72 15 (0) 3 (0) 6 (0) 77 (59) 73 (55)
Abbreviations: M: male, F: female, EX-SM: ex-smoker, C-SM: current smoker, adeno: adenocarcinoma.
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express the BDCAs 1e3.1,2,5 However, in these earlier
studies the identified DCs had not been cultured. Thus, we
suggest that our method of isolation and culture of human
lung DCs is associated with maturation/activation of DCs
and induced co-expression of BDCAs, particularly since the
only sample containing a low percentage (5%) of mature
CD83þ DCs showed low expression of all the BDCAs 1e3.
Interestingly, pulmonary mDCs have also been shown to
express another pDC marker, i.e. the CD123.4Figure 1 CD1a, CD1c (BDCA1), Langerin, BDCA2, BDCA3 and CD8
DCs from patient 3 were highly activated, as shown by strong CD83
all the DC markers. DCs from patient 2 showed low levels or no staTechnique limitations
We acknowledge that: (i) DCs isolated from tissue using
magnetic beads or fluorescence activated cell sorting
may not be induced to co-express these markers.
However, these techniques require comparatively
greater numbers of DCs and are comparatively more
expensive. (ii) flow cytometric analysis would be an
alternative approach to phenotyping the isolated CD1aþ
DCs and identifying BDCA co-expression. However, this is3 immunostaining of lung tissue-derived, CD1aþ-enriched DCs.
expression and a high percentage of the cells were positive for
ining for CD1c (BDCA1), BDCA2, BDCA3 and CD83.
938 M. Tsoumakidou et al.not always feasible when low numbers of cells are iso-
lated. We have previously found that the adherence
method to isolate human lung CD1aþ DCs works well but
we consider it important to report that the method
likely induces maturation and co-expression of myeloid
and plasmacytoid markers. Importantly, the capacity of
environmental influence, albeit experimental, to induce
pulmonary DCs to co-express these markers does high-
light their potential plasticity.
Conclusion
DCs were isolated by adherence from resected human lung
following trypsinisation. In 5 of 8 subject subjects a high
percentage of the cells were CD1aþ Langerhans phenotype.
Interestingly, most of these CD1aþ cells also had been
induced experimentally to express both myeloid and plas-
macytoid BDCA markers. The concept that factors in the
cellular environment, eg viral infection,9 can induce
alternative differentiation pathways has already been
described for bone marrow DCs and we suggest that the
adherence step in vitro induced maturation of our isolated
pulmonary DCs and that there is the potential for a signifi-
cant degree of flexibility/plasticity in pulmonary DCs.
Investigators should be aware and consider this possibility
in future studies.
Conflict of interest
None declared.References
1. Demedts IK, Brusselle GG, Vermaelen KY, Pauwels RA. Identifi-
cation and characterization of human pulmonary dendritic cells.
Am J Respir Cell Mol Biol 2005;32:177e84.
2. Tsoumakidou M, Tzanakis N, Papadaki HA, Koutala H,
Siafakas NM. Isolation of myeloid and plasmacytoid dendritic
cells from human bronchoalveolar lavage fluid. Immunol Cell
Biol 2006;84:267e73.
3. Tsoumakidou M, Zhu J, Wang Z, et al. Immunohistochemical
detection of dendritic cells in human lung tissue. Histopa-
thology 2007;51:565e8.
4. Masten BJ, Olson GK, Tarleton CA, et al. Characterization of
myeloid and plasmacytoid dendritic cells in human lung.
J Immunol 2006;177:7784e93.
5. Bratke K, Lommatzsch M, Julius P, et al. Dendritic cell subsets in
human bronchoalveolar lavage fluid after segmental allergen
challenge. Thorax 2007;62:168e75.
6. Thorley AJ, Goldstraw P, Young A, Tetley TD. Primary human
alveolar type II epithelial cell CCL20 (macrophage inflammatory
protein-3alpha)-induced dendritic cell migration. Am J Respir
Cell Mol Biol 2005;32:262e7.
7. Demedts IK, Bracke KR, Van Pottelberge G, et al. Accumulation
of dendritic cells and increased CCL20 levels in the airways of
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2007;175:998e1005.
8. Mc Dermott R, Ziylan U, Spehner D, et al. Birbeck granules are
subdomains of endosomal recycling compartment in human
epidermal Langerhans cells, which form where Langerin accu-
mulates. Mol Biol Cell 2002;13:317e35.
9. Zuniga EI, McGavern DB, Pruneda-Paz JL, Teng C, Oldstone MB.
Bone marrow plasmacytoid dendritic cells can differentiate into
myeloid dendritic cells upon virus infection. Nat Immunol 2004;
5:1227e34.
